Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study-Reference-Cited by-同舟云学术

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

Published:2013-11-13 Issue:2 Volume:261 Page:267-276
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Gold Ralf, ,Comi Giancarlo,Palace Jacqueline,Siever Arno,Gottschalk Rebecca,Bijarnia Mahendra,von Rosenstiel Philipp,Tomic Davorka,Kappos Ludwig

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

http://link.springer.com/article/10.1007/s00415-013-7115-8/fulltext.html

Reference18 articles.

1. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KR (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277(24):21453–21457

2. European Medicines Agency (2011) Annex I. Summary of product characteristics. Gilenya (fingolimod). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf . Accessed 8 October 2012

3. European Medicines Agency (2012) Revised summary of product characteristics. Gilenya (fingolimod). http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/04/WC500125687.pdf . Accessed 8 October 2012

4. US Food and Drug Administration (2010) Gilenya prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022527s002lbl.pdf . Accessed 8 October 2012

5. US Food and Drug Administration (2012) Gilenya (fingolimod): revised US prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022527s008lbl.pdf . Accessed 8 October 2012

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update and Application of a Deep Learning Model for the Prediction of Interactions between Drugs Used by Patients with Multiple Sclerosis;Pharmaceutics;2023-12-19

2. Sphingosine-1-phosphate receptor modulators in the treatment of early phase multiple sclerosis;Neurologie pro praxi;2023-10-30

3. Index of cardiac-electrophysiological balance in relapsing–remitting multiple sclerosis patients treated with fingolimod;Multiple Sclerosis and Related Disorders;2023-08

4. Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis;Pharmacology & Therapeutics;2023-06

5. The Development of Drug Delivery Systems for Efficient Intracranial Hemorrhage Therapy;Advanced Healthcare Materials;2023-02-03